hotspot -WSS

hotspot

author：entertainment 2025-09-28 15:56:55 - browse：3

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： WHO recommends dropping component of many flu vaccines

WSS

FDA seeks to regulate lab

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Why do women spend more than men on medical expenses?

focus

hotspot

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Inequities make cancer less preventable for women: report

In Memoriam: Notable people who died in 2023

Search called off for baby washed away in Pennsylvania flash flood

Medicare details structure of new drug price negotiation program

Ionis has late

Supreme Court strikes down use of affirmative action

What to watch for from Zogenix and Amicus clinical trials

How one medical school became remarkably diverse

Democrats decry new health bill for going easy on private equity

focus

'Investigate these claims': UFO transparency at center of House hearing

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Senate panel puts off hardest PBM reforms for another day

Device maker Teleflex to acquire urology company for $600M

Dems pitch expanding Medicare power to negotiate drug prices

Democrats decry new health bill for going easy on private equity

hotspot

explore

hotspot

hotspot